Literature DB >> 15237381

Recovery from a variegate porphyria by a liver transplantation.

Nathalie Stojeba1, Carole Meyer, Catherine Jeanpierre, Frédéric Perrot, Christine Hirth, Thierry Pottecher, Jean-Charles Deybach.   

Abstract

The porphyrias are a group of inherited or acquired enzymatic defects of heme biosynthesis. Each type of porphyria has a characteristic pattern of overproduction and accumulation of heme precursors based on the location of dysfunctional enzyme in the heme synthetic pathway. Variegate porphyria, one of the acute hepatic porphyrias, is characterized by a partial reduction in protoporphyrinogen oxidase, the seventh enzyme of the heme biosynthetic pathway. A case of liver transplantation is described with a recovery from a variegate porphyria. Acute porphyria is commonly worsened by a wide variety of medications. We describe a step-by-step perioperative management protocol.

Entities:  

Mesh:

Year:  2004        PMID: 15237381     DOI: 10.1002/lt.20136

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

1.  Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria.

Authors:  Pauline Harper; Staffan Wahlin
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12

2.  A case report of anesthesia management in the liver transplantation recipient with porphyria -A case report-.

Authors:  Hye Won Song; Young Hee Shin; Justin Sangwook Ko; Mi Sook Gwak; Gaab Soo Kim
Journal:  Korean J Anesthesiol       Date:  2012-01-25

3.  High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria.

Authors:  Eliane Sardh; Staffan Wahlin; Mikael Björnstedt; Pauline Harper; Dan E H Andersson
Journal:  J Inherit Metab Dis       Date:  2013-01-23       Impact factor: 4.982

4.  AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function.

Authors:  Makiko Yasuda; David F Bishop; Mary Fowkes; Seng H Cheng; Lin Gan; Robert J Desnick
Journal:  Mol Ther       Date:  2009-10-27       Impact factor: 11.454

5.  RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.

Authors:  Makiko Yasuda; Lin Gan; Brenden Chen; Senkottuvelan Kadirvel; Chunli Yu; John D Phillips; Maria I New; Abigail Liebow; Kevin Fitzgerald; William Querbes; Robert J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

Review 6.  Liver transplantation in the management of porphyria.

Authors:  Ashwani K Singal; Charles Parker; Christine Bowden; Manish Thapar; Lawrence Liu; Brendan M McGuire
Journal:  Hepatology       Date:  2014-07-29       Impact factor: 17.425

7.  Liver Transplantation because of Acute Liver Failure due to Heme Arginate Overdose in a Patient with Acute Intermittent Porphyria.

Authors:  Pascal Frei; Elisabeth I Minder; Natascia Corti; Beat Muellhaupt; Andreas Geier; Heiner Adams; Jean-Paul Dutertre; Alain Rudiger; Philipp Dutkowski; Marco Maggiorini; Christoph C Ganter
Journal:  Case Rep Gastroenterol       Date:  2012-04-19

Review 8.  Nutrients and Porphyria: An Intriguing Crosstalk.

Authors:  Elena Di Pierro; Francesca Granata
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

9.  Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification.

Authors:  Amy Chan; Abigail Liebow; Makiko Yasuda; Lin Gan; Tim Racie; Martin Maier; Satya Kuchimanchi; Don Foster; Stuart Milstein; Klaus Charisse; Alfica Sehgal; Muthiah Manoharan; Rachel Meyers; Kevin Fitzgerald; Amy Simon; Robert J Desnick; William Querbes
Journal:  Mol Ther Nucleic Acids       Date:  2015-11-03       Impact factor: 10.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.